Review On Microrna As Potential Biomarker For Diagnosis And Treatment Of Epilepsy

Background: Epilepsy is a CNS neurological disorder in which normal brain activity is jammed resulting in seizures or periods of unusual behavior. Until now anti-epileptic drugs are only effective in less than one third of epileptic patients, and predicting biomarkers are not available when the specific antiepileptic drugs treated. Advanced studies have showed that miRNA may have a key roll in the pathogenesis of epilepsy. Several target genes and pathways of miRNA which related to the therapeutic methods to epilepsy.

 ;

Method: We searched PubMed from Jan 1,2014 to Jan 1, 2019 using the terms “epilepsy AND microRNA AND biomarker” and “seizure AND microRNA AND biomarker”. We selected articles that featured novel miRNAs in vivo epilepsy models and patients.

 ;

Findings: Decrease the expression of has-miR134 could be a potential non-invasive biomarker to use in diagnosis for the epilepsy patients for using hsa-miR-134 also be identified to distinguish patients with and without epilepsy. miR-181a show significant downregulation in the acute stage, but up regulation in the chronic stage. Other applicable biomarkers for diagnosis of epilepsy are miR-199a,miR124,miR128 etc.

Conclusion: These studies suggest that there can be new developments for diagnosis and treatment of epilepsy patients. Advanced techniques and miRNA combination may produce more effective roles in epilepsy and other disease. These reports will be available to solve the use of miRNAs as biomarkers and novel therapy approaches for epilepsy. To summarize all, researcher who focus on miRNAs should have information on the causes, treatment, and diagnosis of epilepsy. exploration of any of these effects on the efficacy of these drugs is worthwhile.